Linezolid: In infants and children with severe Gram-positive infections

Pediatric Drugs

Volumn 5, Issue 6, 2003, Pages 419-429

  Lyseng Williamson, Katherine A ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; CEFADROXIL; DEXTROMETHORPHAN; FLUOXETINE; GENTAMICIN; LINEZOLID; PAROXETINE; PHENYLPROPANOLAMINE; PHENYTOIN; PSEUDOEPHEDRINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VANCOMYCIN; WARFARIN;

ANEMIA; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BACTERIAL SKIN DISEASE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CHILD; CLINICAL TRIAL; DIARRHEA; DOSE KIDNEY FUNCTION RELATION; DOSE LIVER FUNCTION RELATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG MONITORING; DRUG TOLERABILITY; ENTEROCOCCUS; FOOD DRUG INTERACTION; GRAM POSITIVE BACTERIUM; HEADACHE; HOSPITAL INFECTION; HUMAN; HYPERTENSION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NAUSEA; PANCYTOPENIA; PENICILLIN RESISTANCE; PRIORITY JOURNAL; REVIEW; SEROTONIN SYNDROME; STREPTOCOCCUS PNEUMONIAE; THROMBOCYTOPENIA;

EID: 0037861986     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128072-200305060-00009     Document Type: Review

References (71)

1. Zaoutis T, Dawid S, Kim JO. Multidrug-resistant organisms in general pediatrics. Pediatr Ann 2002; 31 (5): 313-20
2. Noskin GA. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: emerging problems and new prospects for management. Ann Acad Med Singapore 2001 May; 30 (3): 320-31
3. Pharmacia & Upjohn Company. Zyvox: linezolid injection, linezolid tablets, linezolid for oral suspension package insert. Kalamazoo (MI): Pharmacia & Upjohn Company, 2002 Dec
4. Shinabarger DL, Marotti KR, Murray RW, et al. Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions. Antimicrob Agents Chemother 1997; 41: 2132-6
5. Clemett D, Markham A. Linezolid. Drugs 2000 Apr; 59 (4): 815-27
6. Perry CM, Jarvis B. Linezolid: a review of its use in the management of serious Gram-positive infections. Drugs 2001; 61 (4): 525-51
7. Diekema DJ, Jones RN. Oxazolidinones: a review. Drugs 2000 Jan; 1: 7-16
8. Fung HB, Kirschenbaum HL, Ojofeitimi BO. Linezolid: an oxazolidinone anti-microbial agent. Clin Ther 2001 Mar; 23 (3): 356-91
9. Bain KT, Wittbrodt ET. Linezolid for the treatment of resistant gram-positive cocci. Ann Pharmacother 2001 May; 35 (5): 566-75
10. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard. 5th ed. Wayne (PA): NCCLS, 2000 Jan. Publication no. M7-A5
11. National Committee for Clinical Laboratory Standards. Performance Standards for antimicrobial susceptibility testing; twelfth informational supplement. Wayne (PA): NCCLS. 2000 Jan. Publication no. M11-S2
12. Betriu C, Redondo M, Boloix A, et al. Comparative activity of linezolid and other new agents against methicillin-resistant Staphylococcus aureus and teicoplanin-intermediate coagulase-negative staphylococci. J Antimicrob Chemother 2001 Dec; 48 (6): 911-3
13. Tubau F, Fernández-Roblas R, Liñares J, et al. In vitro activity of linezolid and 11 other antimicrobials against 566 clinical isolates and comparison between NCCLS microdilution and Etest methods. J Antimicrob Chemother 2001 May; 47 (5): 675-80
14. Cercenado E, Garcia-Garrote F, Bouza E. In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates. J Antimicrob Chemother 2001 Jan; 47 (1): 77-81
15. Fang C-T, Chang S-C, Chen Y-C, et al. In vitro activity of linezolid against clinical Gram-positive bacterial isolates from Taiwan: an area with a high prevalence of antibiotic resistance. Int J Antimicrob Agents 2001 Sep; 18 (3): 267-70
16. Abb J. In vitro activity of linezolid, quinupristin-dalfopristin, vancomycin, teicoplanin, moxifloxacin and mupirocin against methicillin-resistant Staphylococcus aureus: comparative evaluation by the E test and a broth microdilution method. Diagn Microbiol Infect Dis 2002 Aug: 43 (4): 319-21
17. Mouton JW, Jansz AR. The DUEL study: a multi-center in vitro evaluation of linezolid compared with other antibiotics in the Netherlands. Clin Microbiol Infect 2001 Sep; 7 (9): 486-91
18. Stefani S, Mezzatesta ML, Tempera G, et al. Comparative activity of linezolid against staphylococci and enterococci isolated in Italy. Clin Microbiol Infect 2002 Jun; 8 (6): 368-72
19. Karlowsky JA, Kelly LJ, Critchley IA, et al. Determining linezolid's baseline in vitro activity in Canada using Gram-positive clinical isolates collected prior to its national release. Antimicrob Agents Chemother 2002 Jun; 46 (6): 1989-92
20. Ballow CH, Jones RN, Biedenbach DJ. A multicenter evaluation of linezolid antimicrobial activity in North America. North American ZAPS Research Group. Diagn Microbiol Infect Dis 2002 May; 43 (1): 75-83
21. John MA, Pletch C, Hussain Z. In vitro activity of quinupristin/dalfopristin, linezolid, telithromycin and comparator antimicrobial agents against 13 species of coagulase-negative staphylococci. J Antimicrob Chemother 2002 Dec: 50 (6): 933-8
22. Hilliard NJ, Johnson CN, Armstrong SH, et al. In vitro activity of ertapenem (MK-0826) against multi-drug resistant Streptococcus pneumoniae compared with 13 other antimicrobials. Int J Antimicrob Agents 2002 Aug; 20 (2): 136-40
23. Jones RN, Ballow CH, Biedenbach DJ. Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: report of the Zyvox Antimicrobial Potency Study (ZAPS) in the United States. Diagn Microbiol Infect Dis 2001 May 30; 40 (1-2): 59-66
24. Mutnick AH, Biedenbach DJ, Turnidge JD, et al. Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000. Diagn Microbiol Infect Dis 2002 May; 43 (1): 65-73
25. Grohs P, Kitzis M-D, Gutmann L. In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus. Antimicrob Agents Chemother 2003 Jan; 47 (1): 418-20
26. Kaatz GW, Seo SM. In vitro activities of oxazolidinone compounds U100593 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother 1996 Mar; 40: 799-801
27. Kloss P, Xiong L, Shinabarger DL, et al. Resistance mutations in 23 S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center. J Mol Biol 1999 Nov 19; 294: 93-101
28. Bobkova EV, Patel U, Yah YP, et al. Mechanism of action and resistance to oxazolidinones [abstract no. C1-1810]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Sep 22-25; Chicago, 100
29. Zurenko GE, Todd WM, Hafkin B, et al. Development of linezolid-resistant Enterococcus faecium in two compassionate use program patients treated with linezolid [abstract no. 848]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29; San Francisco
30. Prystowsky J, Siddiqui F, Chosay J, et al. Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrob Agents Chemother 2001 Jul; 45 (7): 2154-6
31. Fines M, Leclercq R. Activity of linezolid against Gram-positive cocci possessing genes conferring resistance to protein synthesis inhibitors. J Antimicrob Chemother 2000; 45: 797-802
32. Welshman IR, Sisson TA, Jungbluth GL, et al. Linezolid absolute bioavailability and the effect of food on oral bioavailability. Biopharm Drug Dispos 2001 Apr; 22 (3): 91-7
33. Gee T, Ellis R, Marshall G, et al. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother 2001 Jun; 45 (6): 1843-6
34. Conte Jr JE, Golden JA, Kipps J, et al. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 2002 May; 46 (5): 1475-80
35. 14C]linezolid to healthy human subjects. Drug Metab Dispos 2001 Aug; 29 (8): 1136-45
36. Wynalda MA, Hauer MJ, Wienkers LC. Oxidation of the novel oxazolidinone antibiotic linezolid in human liver microsomes. Drug Metab Dispos 2000; 28: 1014-7
37. Kearns GL, Abdel-Rahman SM, Blumer JL, et al. Single dose pharmacokinetics of linezolid in infants and children. Pediatr Infect Dis J 2000 Dec; 19 (12): 1178-84
38. Leeder JS, Kearns GL. Pharmacogenetics in pediatrics: implications for practice. Pediatr Clin North Am 1997; 44: 55-77
39. Jungbluth GL, Welshman IR, Hopkins NK, et al. Impact of gestational and postnatal age on linezolid disposition in neonates and young infants [abstract no. 2712]. Pediatr Res 2002 Apr; 51 (Pt 2): 465A
40. Brier ME, Stalker DJ, Aronoff GR, et al. Pharmacokinetics of linezolid in subjects with varying degrees of renal function and on dialysis. J Invest Med 1998 Sep; 46: 276A
41. Hendershot PE, Jungbluth GL, Cammarata SK, et al. Pharmacokinetics of linezolid in patients with liver disease [abstract no. P68]. J Antimicrob Chemother 1999 Jul; 44 Suppl. A: 55
42. Azie NE, Stalker DJ, Jungbluth GL, et al. Effect of linezolid on CYP2C9 using racemic warfarin (W) as a probe [abstract no. PI-81]. Clin Pharmacol Ther 2001 Feb; 69: P21
43. Hendershot PE, Antal EJ, Welshman IR, et al. Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBr. J Clin Pharmacol 2001 May; 41 (5): 563-72
44. Lasher Sisson T, Jungbluth GL, Cammarata SK, et al. A pharmacokinetic evaluation of concomitant administration of linezolid and aztreonam. J Clin Pharmacol 1999; 39: 1277-82
45. Martin JP, Herberg JT, Slatter JG, et al. Although a novel microtiter-plate assay demonstrates that linezolid (PNU-100766) is a weak competitive (reversible) inhibitor of human monoamine oxidase (MAO A), no clinical evidence of MAO A inhibition in clinical trials has been observed [abstract no. A-86]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24-27; San Diego, 27
46. Antal EJ, Hendershot PE, Batts DH, et al. Linezolid, a novel oxazolidinone antibiotic: assessment of monoamine oxidase inhibition using pressor response to oral tyramine. J Clin Pharmacol 2001 May; 41 (5): 552-62
47. McCabe BJ. Dietary tyramine and other pressor amines in MAOI regimens: a review. J Am Dietetic Assn 1986; 86: 1059-64
48. Martin TG. Serotonin syndrome. Ann Emerg Med 1996; 28: 520-6
49. Hammerness P, Parada H, Abrams A. Linezolid: MAOI activity and potential drug interactions [letter]. Psychosomatics 2002 May 30; 43 (3): 248-9
50. Lavery S, Ravi H, McDaniel WW, et al. Linezolid and serotonin syndrome. Psychosomatics 2001 Sep-Oct; 42 (5): 432-4
51. Wigen CL, Goetz MB. Serotonin syndrome and linezolid. Clin Infect Dis 2002 Jun 15; 34 (12): 1651-2
52. Kaplan SL, Patterson L, Edwards KM, et al. Linezolid for the treatment of community-acquired pneumonia in hospitalized children. Linezolid Pediatric Pneumonia Study Group. Pediatr Infect Dis J 2001 May; 20 (5): 488-94
53. Bruss JB, Fleishaker DL, Naberhuis-Stehouwer S, et al. Linezolid vs cefadroxil in the treatment of skin and skin structure infections in children [abstract no. 1596]. Pediatr Res 2002 Apr; 51 (4 Pt 2): 274A plus poster presented at the Annual Meeting of the Pediatric Academic Societies; 2002 May 4-7; Baltimore
54. Kaplan SL, Edge-Padbury B, Naberhuis-Stehouwer S, et al. Linezolid versus vancomycin in the treatment of resistant Gram-positive infections in children [poster no. 642]. 40th Annual Meeting of the Infectious Diseases Society of America; 2002 Oct 24-27; Chicago
55. Rayo Morfin MA. Edge-Padbury B, Naberhuis-Stehouwer S, et al. Linezolid versus vancomycin for the treatment of children with nosocomial pneumonia due to resistant Gram-positive infections in children [poster no. 643]. 40th Annual Meeting of the Infectious Diseases Society of America; 2002 Oct 24-27; Chicago
56. Deville JG, Edge-Padbury B, Naberhuis-Stehouwer S, et al. Empiric treatment with linezolid vs vancomycin for known/suspected gram-positive infections in neonates [poster no. 644]. 40th Annual Meeting of the Infectious Diseases Society of America; 2002 Oct 24-27; Chicago
57. Bruss JB, Fleishaker DL, Naberhuis-Stehouwer S, et al. Linezolid is effective in the treatment of skin and skin structure infections in children due to methicillin-resistant Staphylococcus aureus (MRSA) [abstract no. 1597]. Pediatr Res 2002 Apr; 51 (4 Pt 2): 274A plus poster presented at the Annual Meeting of the Pediatric Academic Societies; 2002 May 4-7; Baltimore
58. Birmingham MC, Rayner CR, Meagher AK, et al. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis 2003 Jan 15; 36 (2): 159-68
59. Moise PA, Forrest A, Birmingham MC. The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin. J Antimicrob Chemother 2002 Dec; 50 (6): 1017-26
60. Herrero IA, Issa NC, Patel R. Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium [letter]. N Engl J Med 2002 Mar 14; 346 (11): 867-9
61. Jones RN, Della-Latta P, Lee LV, et al. Linezolid-resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2002 Feb; 42 (2): 137-9
62. Gonzales RD, Schreckenberger PC, Graham MB, et al. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid [letter]. Lancet 2001 Apr 14; 357 (9263): 1179
63. Pai MP, Gonzales RD, Petrolati JM, et al. Risk factors associated with the development of enterococcal resistance to linezolid [abstract no. K-1194]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Sep 22-25; Chicago, 409
64. Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus [letter]. Lancet 2001 Jul 21; 358 (9277): 207-8
65. Bruss JB, Edge-Padbury B, Naberhuis-Stehouwer S, et al. Hematologic effects of linezolid vs vancomycin in young children [poster no. 645]. 40th Annual Meeting of the Infectious Diseases Society of America; 2002 Oct 24-27; Chicago
66. Gerson SL, Kaplan SL, Bruss JB, et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother 2002; 46: 2723-6
67. Kuter DJ, Tillotson GS. Hematologic effects of antimicrobials: focus on the oxazolidinone linezolid. Pharmacotherapy 2001 Aug; 21 (8): 1010-3
68. Waldrep TW, Skiest DJ. Linezolid-induced anemia and thrombocytopenia. Pharmacotherapy 2002 Jan; 22 (1): 109-12
69. Attassi K, Hershberger E, Alam R, et al. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis 2002 Mar 1; 34 (5): 695-8
70. Halpern M. Linezolid-induced pancytopenia [letter]. Clin Infect Dis 2002 Aug 1; 35 (3): 347-8
71. Orrick JJ, Johns T, Janelle J, et al. Thrombocytopenia secondary to linezolid administration: what is the risk [letter]. Clin Infect Dis 2002 Aug 1; 35 (3): 348-9